A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

NCT00870870 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Gemcitabine
DRUG: Cisplatin
BIOLOGICAL: IMC-A12 (cixutumumab)
BIOLOGICAL: Cetuximab
BIOLOGICAL: IMC-A12 (cixutumumab)
BIOLOGICAL: Cetuximab
DRUG: Carboplatin

Sponsor

Eli Lilly and Company